Novel selective cathepsin K inhibitor safely reduces bone, cartilage progression in osteoarthritis
The new selective cathepsin K inhibitor MIV-711 does not perform better than placebo in easing osteoarthritic pain, a study has shown. However, it substantially decreases bone and cartilage progression with a reassuring safety profile.
Novel selective cathepsin K inhibitor safely reduces bone, cartilage progression in osteoarthritis
08 Jan 2020